NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/27/2026 13:11
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization6,892.71 mln
Float52.46 mln
Earnings Date07/30/2026
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
-1.64
Likely manipulated
1-Year Forecast
146
Strong upside
Relative Strength
29
/ 100
Underperforming
Debt / Equity
1.34
Elevated leverage
ROE
-299
Deeply negative
Business Description
Mirum Pharmaceuticals is a Foster City, California-based company founded in 2018 that develops and sells treatments for rare liver and metabolic diseases. Its approved products include LIVMARLI, a drug for severe itching caused by Alagille syndrome, along with Cholbam and Chenodal, which address bile acid disorders and gallstones respectively. The company also has several treatments in clinical trials targeting liver disease, chronic HDV infection, and fragile X syndrome. Mirum works with a number of partners, including Pfizer, Novartis, and Sanofi, to support its research and commercial operations.
